{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:32:11Z","timestamp":1772253131166,"version":"3.50.1"},"reference-count":25,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T00:00:00Z","timestamp":1570752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GSK BIO","award":["EPI-PERTUSSIS-025 VS NZ SUPP"],"award-info":[{"award-number":["EPI-PERTUSSIS-025 VS NZ SUPP"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>We aimed to evaluate the safety of maternal Tdap; thus, we assessed health events by examining the difference in birth and hospital-related outcomes of infants with and without fetal exposure to Tdap. This was a retrospective cohort study using linked administrative datasets. The study population were all live-born infants in New Zealand (NZ) weighing at least 400 g at delivery and born to women who were eligible for the government funded, national-level vaccination program in 2013. Infants were followed from birth up to one year of age. There were a total of 69,389 eligible infants in the cohort. Of these, 8299 infants were born to 8178 mothers exposed to Tdap (12%), primarily between 28 and 38 weeks gestation as per the national schedule. Among the outcomes, we found a reduced risk for moderate to late preterm birth, low birth weight, small for gestational age, large for gestational age, respiratory distress syndrome, transient tachypnea of newborn, tachycardia or bradycardia, haemolytic diseases, other neonatal jaundice, anaemia, syndrome of infant of mother with gestational diabetes, and hypoglycemia in infants born to vaccinated mothers. There was no association between maternal Tdap, infant Apgar score at 5 min after birth, asphyxia, sepsis or infection, or hypoxic ischemic encephalopathy. Infant exposure to Tdap during pregnancy was associated with a higher mean birthweight (not clinically significant) and higher odds for ankyloglossia and neonatal erythema toxicum diagnoses. There were insufficient observations to allow examination of the effect of Tdap on extreme preterm and very preterm birth, and stillbirth, infant death, or microcephaly. Overall, we found no outcomes of concern associated with the administration of Tdap during pregnancy. NZ Health and Disability Ethics Committee Approval #14\/N.T.A\/169\/AM05.<\/jats:p>","DOI":"10.3390\/vaccines7040147","type":"journal-article","created":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T10:53:03Z","timestamp":1570791183000},"page":"147","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A Retrospective Cohort Study of Safety Outcomes in New Zealand Infants Exposed to Tdap Vaccine in Utero"],"prefix":"10.3390","volume":"7","author":[{"given":"Helen","family":"Petousis-Harris","sequence":"first","affiliation":[{"name":"Vaccine Datalink and Research Group, Department of General Practice &amp; Primary Healthcare, School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Statistics, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lennex","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Statistics, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Watson","sequence":"additional","affiliation":[{"name":"Immunisation Advisory Centre, Department of General Practice &amp; Primary Healthcare, School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Walls","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, University of Otago, PO Box 4345, Christchurch Mail Centre 8140, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikki","family":"Turner","sequence":"additional","affiliation":[{"name":"Immunisation Advisory Centre, Department of General Practice &amp; Primary Healthcare, School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7301-6578","authenticated-orcid":false,"given":"Anna S.","family":"Howe","sequence":"additional","affiliation":[{"name":"Vaccine Datalink and Research Group, Department of General Practice &amp; Primary Healthcare, School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4621-2773","authenticated-orcid":false,"given":"Jennifer B.","family":"Griffin","sequence":"additional","affiliation":[{"name":"Social, Statistical, and Environmental Sciences, RTI International, 3040 East Cornwallis Road, Research Triangle Park, NC 27709-2194, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,10,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/cid\/ciw051","article-title":"Protective effect of contemporary pertussis vaccines: A systematic review and meta-analysis","volume":"62","author":"Fulton","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1586\/14787210.2014.948846","article-title":"Pertussis in Latin America: Epidemiology and control strategies","volume":"12","author":"Flores","year":"2014","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.vaccine.2016.11.004","article-title":"Age-specific effectiveness following each dose of acellular pertussis vaccine among infants and children in New Zealand","volume":"35","author":"Radke","year":"2017","journal-title":"Vaccine"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1073\/pnas.1314688110","article-title":"Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model","volume":"111","author":"Warfel","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Althouse, B.M., and Scarpino, S.V. (2015). Asymptomatic transmission and the resurgence of Bordetella pertussis. BMC Med., 13.","DOI":"10.1186\/s12916-015-0382-8"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"i102","DOI":"10.1093\/ije\/dyq027","article-title":"Tetanus toxoid immunization to reduce mortality from neonatal tetanus","volume":"39","author":"Blencowe","year":"2010","journal-title":"Int. J. Epidemiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S1473-3099(16)30054-8","article-title":"Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: A prospective, active-controlled, observer-blind, randomised phase 4 trial","volume":"16","author":"Tapia","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_8","unstructured":"Centers for Disease Control Prevention (2011). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months\u2014Advisory Committee on Immunization Practices (ACIP), 2011. MMWR. Morb. Mortal. Wkly. Rep., 60, 1424\u20131426."},{"key":"ref_9","unstructured":"Department of Health (2012). Temporary Programme of Pertussis (Whooping Cough) Vaccination of Pregnant Women."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/S0140-6736(14)60686-3","article-title":"Effectiveness of maternal pertussis vaccination in England: An observational study","volume":"384","author":"Amirthalingam","year":"2014","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/cid\/ciu821","article-title":"A case-control study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in England and Wales, 2012\u20132013","volume":"60","author":"Dabrera","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S236","DOI":"10.1093\/cid\/ciw559","article-title":"Sustained effectiveness of the maternal pertussis immunization program in England 3 years following introduction","volume":"63","author":"Amirthalingam","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e20164091","DOI":"10.1542\/peds.2016-4091","article-title":"Effectiveness of vaccination during pregnancy to prevent infant pertussis","volume":"139","author":"Baxter","year":"2017","journal-title":"Pediatrics"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7057","DOI":"10.1016\/j.vaccine.2014.09.052","article-title":"Safety of immunization during pregnancy: A review of the evidence of selected inactivated and live attenuated vaccines","volume":"32","author":"Englund","year":"2014","journal-title":"Vaccine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1016\/j.vaccine.2018.07.011","article-title":"Pertussis Immunisation in Pregnancy Safety (PIPS) Study: A retrospective cohort study of safety outcomes in pregnant women vaccinated with Tdap vaccine","volume":"36","author":"Griffin","year":"2018","journal-title":"Vaccine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1016\/j.vaccine.2015.07.112","article-title":"Key terms for the assessment of the safety of vaccines in pregnancy: Results of a global consultative process to initiate harmonization of adverse event definitions","volume":"33","author":"Munoz","year":"2015","journal-title":"Vaccine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e20173310","DOI":"10.1542\/peds.2017-3310","article-title":"Infant hospitalizations and mortality after maternal vaccination","volume":"141","author":"Sukumaran","year":"2018","journal-title":"Pediatrics"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1001\/jama.2014.14825","article-title":"Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes","volume":"312","author":"Kharbanda","year":"2014","journal-title":"JAMA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1097\/AOG.0000000000001066","article-title":"Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis and Influenza Vaccinations in Pregnancy","volume":"126","author":"Sukumaran","year":"2015","journal-title":"Obstet. Gynecol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1080\/21645515.2016.1157241","article-title":"Maternal and infant outcomes among women vaccinated against pertussis during pregnancy","volume":"12","author":"Berenson","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1097\/AOG.0000000000000862","article-title":"Pregnancy outcomes after antepartum tetanus, diphtheria, and acellular pertussis vaccination","volume":"125","author":"Morgan","year":"2015","journal-title":"Obstet. Gynecol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"g4219","DOI":"10.1136\/bmj.g4219","article-title":"Safety of pertussis vaccination in pregnant women in UK: Observational study","volume":"349","author":"Donegan","year":"2014","journal-title":"BMJ"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/aje\/kww043","article-title":"Risk of preterm or small-for-gestational-age birth after influenza vaccination during pregnancy: Caveats when conducting retrospective observational studies","volume":"184","author":"Kharbanda","year":"2016","journal-title":"Am. J. Epidemiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1001\/jama.2016.14432","article-title":"Tdap vaccination during pregnancy and microcephaly and other structural birth defects in offspring","volume":"316","author":"DeSilva","year":"2016","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1016\/j.vaccine.2013.06.015","article-title":"Pregnant women\u2019s intention to take up a post-partum pertussis vaccine, and their willingness to take up the vaccine while pregnant: A cross sectional survey","volume":"31","author":"Wiley","year":"2013","journal-title":"Vaccine"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/7\/4\/147\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:25:17Z","timestamp":1760189117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/7\/4\/147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,11]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["vaccines7040147"],"URL":"https:\/\/doi.org\/10.3390\/vaccines7040147","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints201907.0210.v1","asserted-by":"object"}]},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,11]]}}}